De novo urothelial carcinoma is relatively rare among post-transplant malignancies and never reported in pediatric kidney transplant recipients. In this paper, we reported one 12-yr-old male case with painless gross hematuria as the initial manifestation of de novo urothelial carcinoma in living donor graft pelvis. We emphasize the importance that cystoscopy and retrograde pyelography of native and transplant kidneys should be performed in all kidney transplant recipients with painless gross hematuria.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1399-3046.2007.00779.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
High-risk non-muscle invasive bladder cancer: Outcomes of patients who cannot benefit from standard of care.
Fr J Urol
December 2024
Department of Urology, Andrology and Renal Transplantation, University Hospital of Besançon, 25000 Besançon, France; University of Franche-Comté, 25000 Besançon, France; Nanomedicine Lab, Imagery and Therapeutics, EA 4662, France. Electronic address:
Introduction: High-grade non-muscle invasive bladder cancer (HG-NMIBC) exposes to a high risk of recurrence and progression. Standard of care includes repeated trans-urethral resection of bladder tumor (reTURBT) and bacillus Calmette-Guérin (BCG) therapy. Not following Standard of care (SOC) may be associated with a worse prognosis.
View Article and Find Full Text PDFUrothelial Urinary Bladder Cancer Is Characterized by Stage-Dependent Aberrations in Metabolism of Bioactive Sphingolipids.
Int J Mol Sci
November 2024
Department of Physiology, Medical University of Bialystok, Mickiewicza 2c, 15-222 Białystok, Poland.
Article Synopsis
- This study investigates the metabolism of bioactive sphingolipids in bladder cancer, focusing on differences between non-muscle-invasive (NMIBC) and muscle-invasive (MIBC) tumors in 48 patients.
- Results showed that MIBC tumors had increased levels of sphingosine-1-phosphate (S1P) and ceramide compared to healthy tissue and NMIBC tumors, indicating stage-dependent changes in sphingolipid metabolism.
- The researchers suggest that the dysregulation of S1P metabolism may play a role in the progression of urothelial bladder cancer as it transitions from NMIBC to MIBC.
Assessing expression patterns of PTGR1, a potential biomarker for acylfulven sensitivity in urothelial carcinoma.
Sci Rep
November 2024
Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Article Synopsis
- Metastatic urothelial carcinoma (mUC) has a poor prognosis, and the study focuses on Prostaglandin Reductase 1 (PTGR1), which is crucial for the effectiveness of acylfulven drugs for treating specific mUC patients with ERCC2 mutations.
- The study evaluated PTGR1 expression in untreated mUC patients using immunohistochemistry (IHC), RNA expression analysis, and targeted genomic panels to identify candidates for clinical trials and assess the potential of PTGR1 as a prognostic biomarker.
- Results indicated that 40% of tumors tested positive for PTGR1 via IHC, demonstrating high sensitivity and specificity in RNA expression analysis, which correlated with tumor mutations and overall
The interplay of mutagenesis and ecDNA shapes urothelial cancer evolution.
Nature
November 2024
Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Article Synopsis
- Advanced urothelial cancer displays significant genetic diversity and involves complex interactions between internal and external mutagens, which contributes to its deadly nature.
- The study revealed that APOBEC3-induced mutations occur early during tumor development, while chemotherapy leads to a surge of later mutations, with both processes affecting the structure of extrachromosomal DNA.
- Findings emphasized the role of circular ecDNA in the development of treatment resistance, specifically through CCND1 amplifications, highlighting key mechanisms that can inform future cancer therapies.
De Novo Urological Malignancies After Renal Transplantation: An Asian 30-Year Experience.
Clin Transplant
July 2024
Department of Urology, Singapore General Hospital, Singapore, Singapore.
Article Synopsis
- - The study analyzes 2,177 kidney transplant recipients over a 30-year period, highlighting a 3.9% incidence of new urological cancers, with renal cell carcinoma being the most prevalent type.
- - Key findings include a mean time of 9.9 years from transplantation to cancer diagnosis and survival rates of 86% and 78% for cancer-specific survival at 5 and 10 years, respectively.
- - The research underscores the need for regular monitoring of kidney transplant patients for urological malignancies to facilitate early detection and treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!